Cargando…

Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

BACKGROUND: Despite numerous therapeutic options, safe and curative therapy is unavailable for most patients with chronic lymphocytic leukemia (CLL). A drawback of current therapies such as the anti-CD20 monoclonal antibody (mAb) rituximab is the elimination of all healthy B cells, resulting in impa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cyr, Matthew G, Mhibik, Maissa, Qi, Junpeng, Peng, Haiyong, Chang, Jing, Gaglione, Erika M, Eik, David, Herrick, John, Venables, Thomas, Novick, Scott J, Courouble, Valentine V, Griffin, Patrick R, Wiestner, Adrian, Rader, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710465/ https://www.ncbi.nlm.nih.gov/pubmed/36442911 http://dx.doi.org/10.1136/jitc-2022-004850

Ejemplares similares

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
por: Mhibik, Maissa, et al.
Publicado: (2019)

Siglec-6 is a Target for Chimeric Antigen Receptor T-cell Treatment of Chronic Lymphocytic Leukemia
por: Kovalovsky, Damian, et al.
Publicado: (2021)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases
por: Vallejo Ardila, Dora Lucia, et al.
Publicado: (2020)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
por: Koller, Paul, et al.
Publicado: (2023)

p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy
por: Lu, Chunwan, et al.
Publicado: (2020)

A(2B) adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models
por: Tay, Apple Hui Min, et al.
Publicado: (2022)

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
por: van den Berg, Joost H, et al.
Publicado: (2020)

Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases
por: Kroemer, Marie, et al.
Publicado: (2020)

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
por: Atkinson, Victoria, et al.
Publicado: (2020)

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Pachynski, Russell K, et al.
Publicado: (2021)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

PD1 blockade enhances K(+) channel activity, Ca(2+) signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer
por: Newton, Hannah S, et al.
Publicado: (2020)

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
por: Boutros, Celine, et al.
Publicado: (2020)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
por: Lampert, Erika J, et al.
Publicado: (2020)

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
por: Yap, Timothy A, et al.
Publicado: (2022)

Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio
por: Crosby, Erika J, et al.
Publicado: (2020)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
por: Tannir, Nizar M, et al.
Publicado: (2022)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
por: Ready, Neal E, et al.
Publicado: (2023)

Siglec-9(+) tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer
por: Wang, Yiying, et al.
Publicado: (2023)

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2021)

Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer
por: Lv, Kunpeng, et al.
Publicado: (2023)

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
por: Wang, Shang-Jui, et al.
Publicado: (2020)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
por: Lai, Anne Y, et al.
Publicado: (2020)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors
por: Zhang, Wu-Hu, et al.
Publicado: (2020)

Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors
por: Naing, Aung, et al.
Publicado: (2020)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
por: Ottaviano, Margaret, et al.
Publicado: (2020)

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020)

Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey
por: Ghosh, Nilasha, et al.
Publicado: (2020)

Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy
por: Buchwald, Zachary S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6172o2l8refi2758lb965ajv03